Mahmoud's Investment Philosophy
"Investing in biotechnology is about recognizing groundbreaking science that transforms patient care, partnering with visionary teams who possess both scientific excellence and commercial acumen, and building sustainable companies that bridge the gap between breakthrough discoveries and life-changing therapies while delivering exceptional value to investors and society."
MAHMOUD MAHMOUDIAN PH.D. - GENERAL PARTNER
Dr. Mahmoud Mahmoudian, FRS, is a distinguished leader in biotechnology and venture capital with over 3 decades of experience spanning drug development, company building, and fund raising. As General Partner at Summit Impact Partners, he leads venture creation and investments in early to late-stage healthcare innovation, bringing transformative therapies to patients across multiple therapeutic areas and modalities.
As a Board Director at Caravan Biologix, Dr. Mahmoudian provides strategic oversight for the development of breakthrough AI-designed mini-CAR therapeutics targeting solid tumors and hereditary diseases. He simultaneously holds key Board positions at multiple biotech companies, including Contera Pharma, developing AI-based precision medicines for neurological disorders, and BioEclipse Therapeutics, driving innovations in immuno-oncology solutions targeting the tumor microenvironment.
During his tenure as Senior Vice President at Sumitomo Pharma America, Dr. Mahmoudian headed global oncology innovation hubs, leading venture investments and external partnerships with academia. He successfully raised $100 Million USD in capital to build academic and venture hubs, established oncology research alliances with prestigious institutions including Columbia, Wistar Institute, Harvard, and Dana-Farber Cancer Institute, and played a pivotal role in the $3 Billion USD acquisition of Roivant (Myovant, Urovant, Enzyvant, Altavant, Spirovant). His leadership in venture creation included launching a corporate fund as an early-stage investor and chairing science and investment committees.
Earlier in his career, Dr. Mahmoudian led global drug development and innovation teams at Merck, GlaxoSmithKline and Ferring with 10 FDA approvals ($15 Billion USD sales) including Adstiladrin®, the first gene therapy approved for bladder cancer and Rebyota®, the first microbiome-based treatment approved for recurring C. difficile infections.
Dr. Mahmoudian is a Fellow of the Royal Society (FRS), holds a Ph.D. and M.Sc. from Imperial College London, combining deep scientific expertise with strong business acumen. His unique blend of scientific knowledge, business strategy, and operational excellence continues to drive innovation in biotechnology and healthcare, creating substantial value for both investors and patients.
Throughout his career, Dr. Mahmoudian has demonstrated exceptional ability in identifying breakthrough technologies, building successful companies with 6 exits totaling over $2 Billion USD, and driving critical innovations from conception to commercialization. His strategic vision and operational expertise have been instrumental in bringing numerous life-changing therapies to market while generating significant returns for investors.
